Filtered By:
Specialty: Internal Medicine
Drug: Aleve
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries
Conclusions Listing of NSAIDs on national EMLs should take account of cardiovascular risk, with preference given to low risk drugs. Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity. Diclofenac should be removed from EMLs.
Please see later in the article for the Editors' Summary
Source: PLoS Medicine - February 12, 2013 Category: Internal Medicine Authors: Patricia McGettigan et al. Source Type: research
